Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with Waldenstrom´s macroglobulinemia

Next Previous
Trial Profile

A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with Waldenstrom´s macroglobulinemia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Rituximab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Therapeutic Use
  • Acronyms Ballondor; WM Study

Most Recent Events

  • 12 Dec 2023 Results estimating the efficacy and safety of the combination of rituximab, bortezomib, lenalidomide and dexamethasone in patients with WM in South Korea, presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 31 Mar 2022 Planned End Date changed from 31 Oct 2023 to 30 Jun 2026.
  • 31 Mar 2022 Planned primary completion date changed from 31 Oct 2021 to 31 May 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top